A readout from the company’s SUMMIT trial put its small molecule bezuclastinib on a collision course with rival Blueprint’s Ayvakit, which Leerink analysts said does not sufficiently treat all patients.
Cogent Jumps on Positive Mid-Stage Mastocytosis Data and NDA Plans Read More »
The Trump administration plans to reinstate the levies Aug. 1 after alerting individual trading partners of their specific duty rates starting Monday.
US preps for August return of country-specific reciprocal tariffs Read More »
UnitedHealth and Centene both pulled their outlooks this year over elevated medical spending in Medicare Advantage and the Affordable Care Act respectively. Now, cost pressures are hitting their smaller peer.
Molina cuts earnings guidance as costs rise in government programs Read More »
The funding will allow the Canadian company to pursue regulatory approvals and build up its manufacturing capabilities and commercial team ahead of a launch anticipated this year.
Kardium pulls in an additional $250M to advance PFA tech Read More »
The partnership will give Chugai access to Gero’s artificial intelligence technology to discover novel targets in aging-related diseases. Chugai will then develop antibody-based drugs based on the findings.
Roche’s Chugai Breaks Into Aging via Potential $1B+ Deal With AI Outfit Gero Read More »
President Donald Trump signed the massive tax bill on Friday, which marks the biggest cuts to Medicaid ever. AdvaMed lauded pro-business provisions of the legislation.
Historic Medicaid cuts to come as Trump signs domestic policy bill Read More »
After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in 2025, according to Jefferies.
The FDA published an early alert, which the agency reserves for potentially high-risk issues.
J&J’s Abiomed recalls heart pump controllers after 3 patients die Read More »
El vínculo entre el consumo de sustancias psicoactivas y la aparición de trastornos mentales es objeto de creciente interés en los ámbitos clínico y científico. Aunque no existe una relación causal única, la evidencia acumulada confirma que muc …
Drogas y mente: ¿Pueden las drogas desencadenar trastornos mentales? Read More »
Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due to resource constraints and reports surfaced that Commissioner Marty Makary tried to have the application rejected.
KalVista Wins OK for First On-Demand Hereditary Angioedema Pill Read More »
